Study of Transplant Related Anemia Treated With Aranesp® (STRATA)
This study has been completed.
Information provided by (Responsible Party):
First received: June 30, 2005
Last updated: April 24, 2013
Last verified: April 2013
The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Study of Transplant Related Anemia Treated With Aranesp® (STRATA)|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Amgen:
Contacts and Locations